Viatris (VTRS) Non-Current Deferred Tax Liability (2019 - 2026)
Viatris (VTRS) recorded quarterly Non-Current Deferred Tax Liability of $870.6 million in Q1 2026, down 2.4% quarter-over-quarter from $892.0 million in Q4 2025, and down 19.58% on a YoY basis from $1.1 billion in Q1 2025.
Viatris (VTRS) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Viatris' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $870.6 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 19.58% year-over-year to $870.6 million; the TTM figure through Mar 2026 stood at $870.6 million (down 19.58% YoY), while the FY2025 annual figure was $892.0 million, down 19.49% from the prior year.
- Non-Current Deferred Tax Liability was $870.6 million for Q1 2026 at Viatris, down from $892.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.8 billion in Q4 2023 to a low of $870.6 million in Q1 2026.
- Historically, Non-Current Deferred Tax Liability has averaged $1.8 billion across 5 years, with a median of $1.7 billion in 2024.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability advanced 14.22% in 2023, then plunged 60.12% in 2024.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $2.4 billion in 2022, then grew by 14.22% to $2.8 billion in 2023, then sank by 60.12% to $1.1 billion in 2024, then decreased by 19.49% to $892.0 million in 2025, then fell by 2.4% to $870.6 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $870.6 million (Q1 2026), $892.0 million (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Viatris | - | - | 1.16 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 870.60 Mn |
| Mar 31, 2026 | 870.60 Mn |
| Dec 31, 2025 | 892.00 Mn |
| Dec 31, 2025 | 892.00 Mn |
| Sep 30, 2025 | 1.03 Bn |
| Sep 30, 2025 | 1.03 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Mar 31, 2025 | 1.08 Bn |
| Mar 31, 2025 | 1.08 Bn |
| Dec 31, 2024 | 1.11 Bn |
| Dec 31, 2024 | 1.11 Bn |
| Sep 30, 2024 | 1.28 Bn |
| Sep 30, 2024 | 1.28 Bn |
| Jun 30, 2024 | 1.57 Bn |
| Jun 30, 2024 | 1.57 Bn |
| Mar 31, 2024 | 1.67 Bn |
| Mar 31, 2024 | 1.67 Bn |
| Dec 31, 2023 | 2.78 Bn |
| Dec 31, 2023 | 2.78 Bn |